Skip to main content
PHARMARESEARCH BIO Co., Ltd. logo

PHARMARESEARCH BIO Co., Ltd. — Investor Relations & Filings

Ticker · 217950 ISIN · KR7217950005 KO Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2020-09-18 Major Shareholding Noti…
Country KR South Korea
Listing KO 217950

About PHARMARESEARCH BIO Co., Ltd.

http://www.pr-bio.co.kr/eng/

PHARMARESEARCH BIO Co., Ltd. is a biopharmaceutical company specializing in regenerative medicine. The company leverages marine biotechnology to research, develop, and produce innovative biological products aimed at enhancing human health. Its core activities center on the development of raw materials for cell and tissue regeneration, such as Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) derived from salmon DNA. The company's research and development pipeline also includes other biological products, such as toxin-based therapeutics, to address various medical and aesthetic needs.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by insiders (executives and major shareholders) to disclose their shareholdings and changes in ownership. This falls under the category of 'Major Shareholding Notification' as it tracks significant ownership changes and insider positions.
2020-09-18 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 1,000 characters) notifying the public about an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting, and mentions that the actual IR materials will be posted later. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most accurate classification.
2020-09-10 Korean
임상시험단계진입ㆍ종료(자율공시)(리엔톡스주 3상 임상시험계획 승인(IND 승인))
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure (자율공시) regarding the approval of a Phase 3 clinical trial (IND approval) for a product called 'Re-N-Tox'. It details the clinical trial stage, purpose, regulatory body (Ministry of Food and Drug Safety), and future plans. Since it is a specific regulatory announcement regarding clinical trial status that does not fit into financial reporting or other specific categories, it is classified as a Regulatory Filing (RNS).
2020-06-09 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as the 5% rule report). It details changes in share ownership, including the addition of special related parties and their respective shareholdings and stock options. This falls under the category of Major Shareholding Notification.
2020-04-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and the relationship between the reporting entity and the issuer (PharmaResearchBio). This type of filing is specifically used to notify the market of significant changes in share ownership (crossing thresholds or changes in special relationships), which aligns with the 'Major Shareholding Notification' category.
2020-03-30 Korean
사업보고서 (2019.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the fiscal year 2019 (2019.01.01-2019.12.31), filed by PharmaResearch Bio Co., Ltd. to the Financial Supervisory Service and Korea Exchange. It contains detailed sections on company overview, history, capital changes, shareholding, and business operations. In the context of Korean corporate filings (DART system), a 'Business Report' (사업보고서) is the equivalent of an Annual Report (10-K). FY 2019
2020-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.